Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novavax and VaxInnate have received the US Department of Health and Human Service (HHS) contract to develop new types of vaccine and new ways to make flu vaccine known as recombinant influenza vaccine.
Subscribe to our email newsletter
Novavax has got $97m for first three years with an option to extend for additional two years for a total contract value of $179.1m.
However, HHS has awarded $117.9m to VaxInnate for the first three years, which can be extended for two additional years, for a total contract value of $196.6m.
Under the contract, Novavax is expected to develop new technology for the production of vaccines while using insect cells to express influenza proteins and create virus-like particles that stimulate a strong immune response in humans.
Novavax and VaxInnate are expected to conduct clinical safety and efficacy studies as well as optimize and validate their manufacturing processes.